Enriched target material for therapeutic isotopes
Making the pure form of lutetium-177 used in cancer drugs like Pluvicto requires starting from a rare, heavily purified metal called ytterbium-176. Almost all of the world's supply of that starting material has come from one country, which is a risky place for the whole medicine to depend on.
Overview
No-carrier-added lutetium-177 (177Lu), the form used in Pluvicto and Lutathera, is made by neutron-irradiating a target of ytterbium enriched to above 96-99% in the stable isotope ytterbium-176, then chemically separating the trace lutetium-177 produced. Only about one in 5,000 atoms in the irradiated target ends up as lutetium-177, and producing the same activity by this route needs roughly a thousand times more enriched starting material than the alternative (but lower-purity) carrier-added route using enriched lutetium-176. There is no accelerator-based alternative: no-carrier-added Lu-177 can only be made by neutron irradiation of Yb-176.
The enrichment step itself -- separating Yb-176 from the other six stable ytterbium isotopes -- has historically been dominated by Russian electromagnetic separators (calutrons), described by the EU's Economic and Social Committee as 100% European dependence on Russia for this specific material. The US Department of Energy's Oak Ridge National Laboratory restarted its own electromagnetic separation in the early 2020s but as of 2022 could only offer 'research quantities' not available for commercial resale, and Western capacity has generally atrophied because the customer base for any single enriched isotope is small and capital costs are high.
The same underlying problem -- a handful of highly specialised, low-throughput separation facilities feeding a fast-growing radioligand therapy market -- applies to other enriched targets in the pipeline (enriched molybdenum-100 for cyclotron-based Mo-99/Tc-99m, enriched gadolinium for astatine-211 routes), making enriched stable-isotope supply a structural constraint on the whole field, not just on lutetium-177.
- There is no feasible accelerator- or proton-based production route for lutetium-177: only neutron irradiation works, which locks the process to a small number of high-flux research reactors and to whichever enriched target is available to them.
- Enrichment of ytterbium-176 requires electromagnetic separators (calutrons), gas centrifuges, or laser separation -- all capital-intensive, low-throughput technologies with very few operators worldwide.
- The customer base for any single enriched stable isotope is small, so for decades it was cheaper to buy Russian material than to build competing Western capacity, and that Western capacity atrophied.
- Chemical recovery and recycling of the expensive enriched ytterbium target after irradiation is technically demanding, so yields and reuse rates limit how far existing enriched stock can be stretched.
- US DOE Isotope Program restarting electromagnetic isotope separation and building the Stable Isotope Production Facility at Oak Ridge National Laboratory, initially for other isotopes (e.g. xenon-129) with stable-isotope enrichment as a stated strategic priority including ytterbium-176.
- EU SAMIRA action plan and Euratom research calls specifically funding alternative, non-Russian ytterbium-176 production routes.
- Radiopharmaceutical manufacturers (Novartis, ITM, others) reported to be pursuing multiple, geographically diversified Yb-176 supply agreements to reduce single-country exposure.
Similar pages
not linked directly; found by shared links- CompanyNiowave
Shares Astatine-211, Molybdenum-99, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).
- CompanyNorthStar Medical Radioisotopes
Shares Molybdenum-99 supply, Actinium-225 supply, Molybdenum-99, Research reactors for medical isotopes (Mo-99, Lu-177, I-131).
- CompanySHINE Technologies
Shares Molybdenum-99 supply, Molybdenum-99, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).
- CompanyANSTO (Australian Nuclear Science and Technology Organisation)
Shares Molybdenum-99 supply, Molybdenum-99, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).
- BottleneckClinical trial capacity for radioligand therapy
Shares Actinium-225 supply, Lutetium-177 radioligand therapy, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Novartis.
- RoadmapIsotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium
Shares NTP Radioisotopes, Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier, Molybdenum-99, Research reactors for medical isotopes (Mo-99, Lu-177, I-131).
- TechnologyMolybdenum-99/technetium-99m generators
Shares Molybdenum-99, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Technetium-99m and the tag supply chain.
- BottleneckManufacturing cost and time for living and radioactive medicines
Shares Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier, ITM Isotope Technologies Munich, Actinium-225 supply, Curium.